Overview

* Genelux ( GNLX ) Q2 net loss of $7.5 mln beats analyst expectations, per LSEG data

* Company advances Olvi-Vec towards potential registration in platinum-resistant/refractory ovarian cancer

* InJuly, Eric Groen appointed as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development to strengthen leadership team

Outlook

* Company anticipates cash runway into Q3 2026

Result Drivers

* CLINICAL TRIAL COSTS - Increase in R&D expenses driven by Phase 3 OnPrime trial costs

* LEADERSHIP ENHANCEMENT - Appointment of Eric Groen to strengthen executive team

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net Beat -$7.46 -$7.81

Income mln mln (6

Analysts

)

Q2 Beat -$7.79 -$7.86

Income mln mln (5

from Analysts

Operatio )

ns

Q2 $7.79

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Genelux Corp ( GNLX ) is $13.00, about 72.4% above its August 6 closing price of $3.59

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)